Product Images Gabapentin

The text describes a chart showing the average pain scores during a medication trial. The trial involved a four-week period during which the medication dose was increased, followed by an eight-week period during which a fixed dose was given. The medications being studied were a placebo and gabapentin at a dose of 3600 mg/day. The chart displays the baseline score and pain scores at weeks 1-8.*

The text provides statistical data regarding the efficacy of treatments for controlled PHN (Postherpetic neuralgia) in two different studies. The figure shows the proportion of responders, i.e., patients with a pain score reduction of more than 50% at the endpoint of the study. The results indicate that in study 1, 34% of patients responded positively to treatment, while in study 2, the value was not available. The text also mentions the medication dosages used in these studies: GEP 3600, GBP 1800 and GBP 2400.*

This text appears to be a formula for calculating the creatinine clearance rate (CLCr) of a patient. The CLCr is important in assessing kidney function, as it measures the rate at which creatinine, a waste product that is filtered through the kidneys, is cleared from the body. The formula takes into account the patient's age, weight, and serum creatinine level, and adjusts the weight multiplier for female patients. This information could be useful for doctors or medical professionals in assessing kidney function in their patients.*